Who this is for: GPs and medical officers managing adults with type 2 diabetes in the OPD, using the ADA Standards of Care in Diabetes as the reference framework adapted to Pakistani drug availability.
Epidemiology in Pakistan
Pakistan has one of the highest diabetes prevalences in the world: national survey data and IDF estimates put adult prevalence around 26 to 31 percent, roughly 33 million adults, the third largest national count globally, with nearly a quarter of cases undiagnosed. Onset is a decade earlier than in European populations and occurs at lower BMI, which is why screening thresholds are lower for South Asians. Most care happens in general practice, and most complications are preventable there.
Screening and diagnosis
Screen (per ADA): all adults from age 35; earlier if BMI is 23 or more (Asian cutoff) plus any risk factor such as family history, hypertension, dyslipidaemia, gestational diabetes, or PCOS. Repeat 3-yearly if normal.
Diagnostic thresholds (any one, confirmed on a second test unless unequivocal hyperglycaemia):
- Fasting plasma glucose 126 mg/dL (7.0 mmol/L) or more
- 2-hour OGTT glucose 200 mg/dL or more
- HbA1c 6.5 percent or more
- Random glucose 200 mg/dL or more with classic symptoms
Prediabetes: FPG 100 to 125, 2-hour 140 to 199, HbA1c 5.7 to 6.4 percent; manage with structured lifestyle change targeting 7 percent weight loss, and consider metformin in younger, obese patients per ADA.
Beware HbA1c pitfalls common in Pakistan: iron deficiency, haemoglobinopathies (thalassaemia trait) and recent transfusion distort HbA1c; use glucose criteria when in doubt.
Baseline workup, cheapest first
FPG and HbA1c; lipid profile; creatinine with eGFR; urine albumin-to-creatinine ratio; ALT; ECG in patients over 40 or with cardiac symptoms; dilated fundus examination or retinal photo referral at diagnosis and then per findings; documented foot examination (monofilament if available, otherwise pinprick and pulses) at diagnosis and annually.
Glycaemic targets, stratified
- Most non-pregnant adults: HbA1c below 7 percent.
- Younger, recently diagnosed, low hypoglycaemia risk: tighter (6.5 percent) if achievable safely.
- Older adults per ADA: healthy elderly, below 7 to 7.5 percent; complex or intermediate health, below 8 percent; very complex or poor health and limited life expectancy, avoid reliance on HbA1c and simply prevent symptomatic hyper- and hypoglycaemia. De-intensify sulfonylureas and insulin in frail over-70s; hypoglycaemia in this group causes falls, arrhythmia and death.
Management
Lifestyle first, always: medical nutrition therapy adapted to Pakistani diets (portion control of rice and roti, reducing sugared tea and drinks), 150 minutes of moderate activity weekly, weight loss of 5 to 10 percent, smoking cessation.
Pharmacotherapy per ADA:
- Metformin remains the foundation: start 500 mg once or twice daily with food, titrate to 1000 mg twice daily as tolerated; avoid when eGFR is below 30, halve ambition at 30 to 45. Cheap and universally available as DRAP-registered generics.
- Compelling-indication drugs independent of HbA1c: with established ASCVD, heart failure or CKD (eGFR below 60 or ACR 30 mg/g or more), add an SGLT2 inhibitor (empagliflozin or dapagliflozin, both available in Pakistan as affordable generics) or a GLP-1 receptor agonist with proven benefit. SGLT2 inhibitors need sick-day advice (hold during vomiting, fasting, or dehydration; counsel on genital hygiene).
- Otherwise add-on choices by cost and hypoglycaemia risk: sulfonylureas (gliclazide preferred over glibenclamide, especially in elderly and renal impairment), DPP-4 inhibitors (sitagliptin generics), pioglitazone (avoid in heart failure).
- Insulin when HbA1c is above 10 percent, glucose above 300 mg/dL, catabolic symptoms, or oral failure: start basal insulin 10 units or 0.1 to 0.2 units per kg at night, titrate 2 units every 3 days to fasting 80 to 130 mg/dL, and teach hypoglycaemia recognition on day one.
- Ramadan planning is standard care in Pakistan: risk-stratify before the month, shift the larger dose to iftar, prefer agents with low hypoglycaemia risk, and pre-agree glucose thresholds for breaking the fast.
Cardiovascular protection: BP target below 130/80; statin for nearly all diabetics over 40 (moderate intensity, high intensity with ASCVD); do not add aspirin for primary prevention routinely.
Red flags: refer or admit
Glucose above 400 mg/dL with vomiting or drowsiness (rule out HHS or DKA), foot ulcer or gangrene (same-week surgical referral), sudden visual loss, eGFR below 30 or rapidly rising creatinine, pregnancy with diabetes, and suspected type 1 in a lean young patient with ketosis.
Follow-up schedule
HbA1c every 3 months until at target, then 6-monthly; annual ACR, eGFR, lipids, foot and eye checks; BP and weight at every visit. Structured recall is the difference between guideline care and drift; the MyPatient EHR flags overdue HbA1c, foot and retinal checks on its problem list so the annual bundle actually happens. Share the patient guide to share for self-care basics.
Key points
- Screen South Asians from BMI 23 and age 35; confirm diagnosis with a second test.
- Target HbA1c below 7 percent for most; relax to below 8 percent or symptom control in frail elderly.
- Metformin first; SGLT2i or GLP-1 RA whenever ASCVD, HF or CKD exists, regardless of HbA1c.
- Prefer gliclazide over glibenclamide when sulfonylureas are used; teach hypoglycaemia care.
- Annual ACR, eGFR, foot and eye screening prevents the expensive complications.
- Plan Ramadan medication changes proactively every year.
References
- Standards of Care in Diabetes. American Diabetes Association, 2026.
- IDF Diabetes Atlas, 10th edition. International Diabetes Federation, 2021.
- Management of Hyperglycemia in Type 2 Diabetes: ADA-EASD Consensus Report, 2022.
- Diabetes and Ramadan: Practical Guidelines. IDF and DAR International Alliance, 2021.
- Clinical Practice Recommendations for Type 2 Diabetes. Pakistan Endocrine Society, 2022.
Clinical judgement and local protocols take precedence.